These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1072 related items for PubMed ID: 27447711

  • 1. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S, Ham JS, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
    Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
    [Abstract] [Full Text] [Related]

  • 2. Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study.
    Liu S, Qiu B, Chen L, Wang F, Liang Y, Cai P, Zhang L, Chen Z, Liu S, Liu M, Liu H.
    Radiat Oncol; 2015 May 27; 10():118. PubMed ID: 26014133
    [Abstract] [Full Text] [Related]

  • 3. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
    Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL.
    Int J Radiat Oncol Biol Phys; 2016 Jun 01; 95(2):673-9. PubMed ID: 27034176
    [Abstract] [Full Text] [Related]

  • 4. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, Beal K, Amini A, Patil T, Kavanagh BD, Camidge DR, Braunstein SE, Boreta LC, Balasubramanian SK, Ahluwalia MS, Rana NG, Attia A, Gettinger SN, Contessa JN, Yu JB, Chiang VL.
    J Clin Oncol; 2017 Apr 01; 35(10):1070-1077. PubMed ID: 28113019
    [Abstract] [Full Text] [Related]

  • 5. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
    Zhang Q, Zhang X, Yan H, Jiang B, Xu C, Yang J, Chen Z, Su J, Wu YL, Zhou Q.
    Thorac Cancer; 2016 Nov 01; 7(6):648-654. PubMed ID: 27755835
    [Abstract] [Full Text] [Related]

  • 6. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
    Yang JJ, Zhou C, Huang Y, Feng J, Lu S, Song Y, Huang C, Wu G, Zhang L, Cheng Y, Hu C, Chen G, Zhang L, Liu X, Yan HH, Tan FL, Zhong W, Wu YL.
    Lancet Respir Med; 2017 Sep 01; 5(9):707-716. PubMed ID: 28734822
    [Abstract] [Full Text] [Related]

  • 7. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
    Gui Q, Liu J, Li D, Xu C.
    World J Surg Oncol; 2017 Oct 16; 15(1):184. PubMed ID: 29037198
    [Abstract] [Full Text] [Related]

  • 8. Clinical research on stereotactic radiosurgery combined with epithermal growth factor tyrosine kinase inhibitors in the treatment of brain metastasis of non-small cell lung cancer.
    Jia F, Cheng X, Zeng H, Miao J, Hou M.
    J BUON; 2019 Oct 16; 24(2):578-584. PubMed ID: 31128009
    [Abstract] [Full Text] [Related]

  • 9. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.
    Jiang T, Su C, Li X, Zhao C, Zhou F, Ren S, Zhou C, Zhang J.
    J Thorac Oncol; 2016 Oct 16; 11(10):1718-28. PubMed ID: 27237825
    [Abstract] [Full Text] [Related]

  • 10. Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC).
    Zhu Q, Sun Y, Cui Y, Ye K, Yang C, Yang D, Ma J, Liu X, Yu J, Ge H.
    Oncotarget; 2017 Feb 21; 8(8):13304-13311. PubMed ID: 28076323
    [Abstract] [Full Text] [Related]

  • 11. [Timing of Whole Brain Radiotherapy on Survival of Patients with EGFR-mutated 
Non-small Cell Lung Cancer and Brain Metastases].
    Liu G, Zhang X, Tian C, Xia G, Liu P, Zhang Q, Li X, Zhang H, Qin N, Wang J, Zhang S.
    Zhongguo Fei Ai Za Zhi; 2016 Aug 20; 19(8):501-7. PubMed ID: 27561798
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant.
    Zhao L, Cai X, Chen D, Ye X, Gao M, Lu L, Su H, Su M, Hou M, Xie C.
    Radiat Oncol; 2019 Dec 31; 15(1):3. PubMed ID: 31892337
    [Abstract] [Full Text] [Related]

  • 13. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
    Miyawaki E, Kenmotsu H, Mori K, Harada H, Mitsuya K, Mamesaya N, Kawamura T, Kobayashi H, Nakashima K, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Endo M, Nakasu Y, Gon Y, Takahashi T.
    Int J Radiat Oncol Biol Phys; 2019 Jul 01; 104(3):604-613. PubMed ID: 30851347
    [Abstract] [Full Text] [Related]

  • 14. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.
    Soon YY, Leong CN, Koh WY, Tham IW.
    Radiother Oncol; 2015 Feb 01; 114(2):167-72. PubMed ID: 25583566
    [Abstract] [Full Text] [Related]

  • 15. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH, Lin D, Xu L, Wang Q, Hu HH, Xu HP, He ZY.
    Oncotarget; 2017 Jan 10; 8(2):3412-3421. PubMed ID: 27926500
    [Abstract] [Full Text] [Related]

  • 16. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.
    Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbé C, Mascaux CM, Martin P, Kamel-Reid S, Tsao MS, Pintilie M, Liu G, Bradbury PA, Feld R, Leighl NB, Chung C, Shepherd FA.
    Radiother Oncol; 2017 May 10; 123(2):195-202. PubMed ID: 28363487
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses.
    Zhao B, Wang Y, Wang Y, Chen W, Zhou L, Liu PH, Kong Z, Dai C, Wang Y, Ma W.
    Aging (Albany NY); 2020 Jul 15; 12(14):14244-14270. PubMed ID: 32669477
    [Abstract] [Full Text] [Related]

  • 18. Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis.
    Zhao Y, Li S, Yang X, Chu L, Wang S, Tong T, Chu X, Yu F, Zeng Y, Guo T, Zhou Y, Zou L, Li Y, Ni J, Zhu Z.
    Int J Cancer; 2022 Apr 15; 150(8):1318-1328. PubMed ID: 34914096
    [Abstract] [Full Text] [Related]

  • 19. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.
    Chen Y, Wei J, Cai J, Liu A.
    BMC Cancer; 2019 Aug 09; 19(1):793. PubMed ID: 31399067
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, Lee JS.
    Lung Cancer; 2012 Sep 09; 77(3):556-60. PubMed ID: 22677429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.